Alphatec Holdings, Inc. (ATEC) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. Alphatec Holdings, Inc. is a medical technology company focused on the design and development of technology for the surgical treatment of spinal disorders. The company operates through subsidiaries including Alphatec Spine, SafeOp Surgical, and EOS imaging. As of July 28, 2026, there were 154,451,076 shares of common stock outstanding.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Revenue | $405,621 |
| Gross Profit | $290,574 |
| Gross Margin | 71.6% |
| Operating Loss | $(24,489) |
| Net Loss | $(59,687) |
| Diluted Net Loss Per Share | $(0.38) |
| Cash and Cash Equivalents | $118,662 |
| Total Debt (Principal) | $685,012 |
| Net Cash Provided by Operating Activities | $21,803 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 14% year-over-year (YoY) to $405.6 million for the six months ended June 30, 2026, driven by increased product volume, surgeon user base expansion, and new product adoption.
- Operating Expenses: Total operating expenses rose 4% YoY to $315.1 million. Sales, general, and administrative (SG&A) expenses increased 10% due to higher compensation and variable selling costs. Conversely, litigation-related expenses decreased 97% to $0.4 million, primarily due to a settlement in the prior year.
- Debt Restructuring: In May 2026, the company entered a new $300 million credit facility with JP Morgan ($175M term loan, $125M revolver) to replace prior Braidwell and MidCap facilities. This resulted in an $11.9 million loss on debt extinguishment recorded in the current period.
- Liquidity: Cash and cash equivalents decreased from $160.8 million at year-end 2025 to $118.7 million at June 30, 2026, primarily due to investing activities ($42.6M used) and financing repayments.
Guidance, Outlook, and Risks
Management Commentary: Management attributes revenue growth to the expansion of the surgeon user base and the commercial launch of new products. The company continues to invest in its strategic distribution channel and R&D. The new JP Morgan credit agreement provides liquidity through 2031, subject to financial covenants including a Senior Secured Net Leverage Ratio not exceeding 3.00 to 1.00.
Risks and Contingencies:
- Debt Obligations: The company has significant debt maturities, including $63.3 million in 2026 Notes (repaid in full on July 30, 2026, per subsequent events) and $405 million in 2030 Convertible Notes.
- Inventory: The company maintains substantial inventory levels to meet surgical demands, creating a risk of obsolescence. A write-down for excess and obsolete inventory of $8.1 million was recorded in the first half of 2026.
- Litigation: While no single matter is currently deemed material, the company notes that litigation outcomes are unpredictable and could materially affect future results.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new JP Morgan Credit Agreement covenants (Leverage and Fixed Charge Coverage ratios) starting September 30, 2026.
- Convertible Notes: Monitor the conversion status of the $405 million 2030 Notes and the impact of the capped call transactions on potential dilution.
- Inventory Valuation: Review the assumptions used for the $8.1 million inventory write-down and assess future obsolescence risks given the $194.9 million inventory balance.
- Cash Burn vs. Operating Cash Flow: Analyze the sustainability of the $21.8 million operating cash flow against the $42.6 million investing outflow and ongoing debt service requirements.
- Subsequent Event: Confirm the full repayment of the 2026 Notes on July 30, 2026, and its impact on the balance sheet.